Nexplanon Contraceptive Effectiveness and Duration

Approved Duration

• The etonogestrel implant (Nexplanon) provides contraceptive protection for 3 years from the time of insertion, as recommended by the American Academy of Pediatrics 1, 2, 3, 4, 5, 6, 7
• After 3 years, the device should be replaced with a new implant if continued contraceptive protection is desired, according to the FDA approval 1, 2, 3, 4, 5, 6, 7

Contraceptive Efficacy During Approved Period

• Nexplanon demonstrates exceptional effectiveness with a failure rate of less than 0.05% during the 3-year approved duration, making it one of the most effective reversible contraceptive methods available 1, 2, 3, 4, 5, 6, 7
• Both typical-use and perfect-use failure rates are less than 1%, as reported by the American College of Obstetricians and Gynecologists 1, 2, 3, 4, 5, 6, 7

Important Clinical Considerations

• Backup contraception (condoms or abstinence) should be used for at least the first week after insertion for full contraceptive efficacy, as recommended by the Centers for Disease Control and Prevention 1, 3, 5
• The 84% continuation rate at 1 year reflects high user satisfaction despite common irregular bleeding patterns, according to the Society for Adolescent Health and Medicine 2, 4, 6, 7

Extended Use and Drug Interactions

• Evidence indicates the implant may remain effective for up to 4 years, with no documented pregnancies during the fourth year in recent studies, although this is not currently recommended for standard clinical practice 8, 9
• For patients on certain antiretroviral medications (efavirenz, nevirapine, or most protease inhibitors), the contraceptive efficacy may be reduced, and alternative or additional contraceptive methods should be used, as advised by the World Health Organization 8, 9, 10

Contraceptive Efficacy of Nexplanon with Medications

Drug Interactions with Nexplanon

• The National Institutes of Health recommends that patients taking efavirenz, nevirapine, or most protease inhibitors use alternative or additional contraceptive methods during treatment and for the duration of the implant, as these medications can reduce Nexplanon effectiveness 11, 12, 13
• The American Academy of Pediatrics notes that only hepatic enzyme-inducing drugs, such as certain antiretroviral medications, can impair Nexplanon efficacy, whereas standard oral antibiotics do not interfere with its effectiveness 11, 12, 13

Contraceptive Guidance

• The National Institutes of Health guidance suggests that patients on enzyme-inducing antiretrovirals should use alternative or additional contraceptive methods during treatment and for the duration of the implant if exposed to efavirenz, nevirapine, or most protease inhibitors 11, 12, 13
• Dual protection with condoms is essential for STI protection, regardless of antibiotic use, as recommended by the American Academy of Pediatrics 11, 12, 13

Bleeding Patterns with Nexplanon

Understanding Nexplanon-Related Bleeding

• Approximately 22% of Nexplanon users experience amenorrhea, while 34% have infrequent spotting, and about 7% report frequent bleeding and 18% experience prolonged bleeding, particularly during the first year of use, according to the Centers for Disease Control and Prevention 14
• The bleeding irregularities associated with Nexplanon are generally not harmful and may or may not decrease with continued implant use, as stated by the Centers for Disease Control and Prevention 14
• First, rule out underlying gynecological problems, including STDs, pregnancy, or new pathologic uterine conditions like polyps or fibroids, as recommended by the Centers for Disease Control and Prevention 14

Clinical Management of Nexplanon Bleeding

• If no underlying problem is found and treatment is desired, consider short-term options during bleeding days, such as NSAIDs for 5-7 days, as suggested by the Centers for Disease Control and Prevention 14
• Provide pre-insertion counseling about expected bleeding changes, as enhanced counseling reduces discontinuation rates, according to the Centers for Disease Control and Prevention 14

Drug Interactions

• Anticoagulants and antiplatelet agents increase bleeding risk through their pharmacologic mechanisms, not through interaction with hormonal contraceptives, as reported by the American College of Chest Physicians 15, the American Heart Association 16, and the American College of Chest Physicians 17

Contraceptive Effectiveness of the Nexplanon Implant

Failure Rates

• The Nexplanon implant demonstrates a failure rate of < 0.05 % over the three‑year approved use period, outperforming sterilization procedures. 18
• Both typical‑use and perfect‑use failure rates for Nexplanon are reported to be < 1 % during the three‑year duration. 18

Counseling on Bleeding Patterns

• Irregular bleeding, the most common side effect of Nexplanon, does not indicate reduced contraceptive efficacy and patients should be reassured accordingly. 18

Nexplanon (Etonogestrel Implant): Approved Duration, Effectiveness, and Management

Approved Duration and Effectiveness

• The American Academy of Pediatrics and the CDC recommend that the etonogestrel implant provides contraceptive protection for 3 years from insertion. 19, 20, 21
• After the 3‑year period, the device should be removed and replaced with a new implant if continued contraception is desired. 19
• During the FDA‑approved 3‑year period, Nexplanon’s failure rate is < 0.05 %, making it one of the most effective reversible contraceptives. 19
• Both typical‑use and perfect‑use failure rates remain below 1 % throughout the approved 3‑year period. 19, 20, 21
• The 1‑year continuation rate is ≈ 84 %, reflecting high user satisfaction despite irregular bleeding patterns. 19

Clinical Management at the End of Approved Use

• At the 3‑year mark, clinicians should schedule a removal appointment for the implant. 21
• When removal is performed at 3 years, the implant can be replaced immediately with a new device without requiring a backup contraceptive method. 20, 21
• If a patient requests use beyond 3 years, clinicians must inform the patient that this constitutes off‑label (non‑FDA‑approved) use. 19

Backup Contraception Guidance

• Backup contraception is required for 7 days after the initial insertion when the implant is placed more than 5 days after the start of menstrual bleeding. 20, 21